Company: ENTXW
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001178913-25-003852
Chunk: 31

Company: Entera Bio Ltd.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 2
Chunk 31
---
 its activities and has incurred an accumulated deficit and negative cash flows from operating activities since inception. As of the date of this Quarterly Report, we believe that our existing cash resources will be sufficient to support the Company’s operations under its current plans through the middle of the third quarter of 2026. These factors raise substantial doubt as to the Company's ability to continue as a going concern. The unaudited condensed consolidated financial statements contained in this Quarterly Report have been prepared on a going concern basis and do not include any adjustments that may be necessary should we be unable to continue as a going concern. If we are unable to finance our operations, our business would be in jeopardy, and we might not be able to continue operations and might have to liquidate our assets. In that case, investors might receive less than the value at which those assets are carried on our financial statements, and it is likely that investors would lose all or a part of their investment.

28

Cash Flows

Nine Months Ended September 30, 2025 compared to Nine Months Ended September 30, 2024

The following table sets forth the primary sources and uses of cash for each of the periods set forth below:

​ Nine Months Ended September 30,(unaudited) ​ 2025  2024 ​ (In thousands) Net Cash used in operating activities $(5,537) $(5,351)Net Cash used in investing activities $(80) $- Net Cash provided by financing activities $13,536  $1,259 Effect of Exchange Rate change on cash and cash equivalents $29   - Net increase (decrease) in cash and cash equivalents $7,919  $(4,092)

Net Cash Used in Operating Activities

Net cash used in operating activities for the nine months ended September 30, 2025 was $5.5 million, consisting primarily of our operating loss of  $8.5 million, which was partially offset by approximately $2.1 million of share-based compensation and depreciation expenses and a decrease of approximately $0.9 million in our net operating assets and liabilities.

Net cash used in operating activities for the nine months ended September 30, 2024 was $5.4 million, consisting primarily of our operating loss of $7.2 million and an increase of $0.2 million in our net operating assets and liabilities, which was partially offset by approximately $2.0 million of